• Lepu Biopharma posted revenue of RMB 522.4 million, up 12.1% year over year.
• Profit fell to RMB 24.8 million from RMB 29.3 million.
• Sales of MEIYOUHENG and PUYOUHENG climbed to RMB 371.3 million, more than doubled year over year.
• Licensing revenue slid to RMB 148.7 million from RMB 309 million, mainly tied to CMG901 and MRG007 milestones.
• R&D expenses were RMB 208.3 million versus RMB 202.2 million; cash and cash equivalents totaled RMB 684.6 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lepu Biopharma Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260819-12289959), on August 19, 2026, and is solely responsible for the information contained therein.